Carrick Therapeutics, an oncology focused biopharmaceutical company, has announced a collaboration with Arvinas Inc. and Pfizer Inc. for a clinical trial involving the combination of two drugs, samuraciclib (CT7001) and vepdegestrant (ARV-471).
The trial aims to evaluate the effectiveness of this innovative combination, which involves Carrick's samuraciclib, an oral CDK7 inhibitor, and Arvinas' vepdegestrant, an investigational oral PROTAC® estrogen receptor protein degrader.
This collaboration and supply agreement marks a significant step forward for Carrick Therapeutics in their pursuit of developing highly differentiated therapies for oncology.
The Phase 1b/2 clinical trial will provide valuable insights into the potential benefits of combining these two drugs in the treatment of cancer.
The agreement also strengthens the partnership between Carrick Therapeutics, Arvinas Inc., and Pfizer Inc. in their joint efforts to advance cancer research and development.